Over almost 70 years, Krka has made some bold moves to position itself as a world-leading generic pharmaceutical company.
Our product and service sales annually amount to €1.72 billion. Our high-quality, safe and effective medicines are used to treat more than 50 million patients in more than 70 countries every day. Stable sales growth, investments, multiple development projects, and sound business performance have seen us grow into a pharmaceutical business group of the controlling company in Slovenia and many subsidiaries and representative offices in more than 45 countries. Krka’s sound business performance is the key to boosting business value, a stable dividend policy, and high dividend yield.
STABLE DIVIDEND POLICY
Krka’s annual dividend yield averaged almost 5% over the last ten years, outperforming the generic pharmaceutical production sector. We endeavour to deliver steady intra-annual dividend growth, which averaged 14.1% over the last ten years.
It can be expected that a stable dividend policy will be pursued going forward, too. Account being taken of the Krka Group’s investment needs and financial requirements, we intend to allocate at least fifty percent of net profit earned by majority shareholders to dividend payout.
STRONG CASH FLOW FROM OPERATING ACTIVITIES
Every year, our operating activities generate a strong cash flow, which augments the sustainability and profitability of our operations; sound working capital management; and stellar performance of the Krka Group business model.
A strong cash flow means we can regularly discharge all current operating liabilities, cover capital expenditure, research and investment costs, and dividend payments, and implement a treasury share repurchase programme.
STABLE CAPITAL STRUCTURE
An absence of indebtedness coupled with a strong cash flow from operations contributes to Krka’s sound financial standing. Financial surpluses are reported each year, and investors receive their returns in dividends and through a treasury share repurchase programme. Financial surplus translates into investments, long-term business connections, acquisitions and repurchase of treasury shares. It is a tool for pursuing a stable dividend policy and alleviating pressures in time of economic turbulence.
Our financial discipline is highly regarded by our business partners. Together with financial accountability, it offers increased flexibility and resilience and supports further growth.
Sustainable development is one of our core principles. We are a socially responsible company that cares for its employees and takes an interest in the wider community and the environment in which it operates. We devote effort to protecting the natural environment and work to maintain a strong corporate integrity.
WE CREATE INNOVATIVE PHARMACEUTICAL FORMS AND PROCESSES
We apply novel, sophisticated approaches and methods in development phases. This enables us to develop medicines in complex pharmaceutical forms and make them first movers. Thanks to our innovative procedures, our products are most advanced, meet the most stringent quality standards, and are available at affordable prices.
WIDE RANGE OF PRODUCTS
Krka’s innovative products have been tested in everyday clinical practice and are accessible to a wide range of users. We offer a wide range of medicines in the key therapeutic areas: cardiovascular diseases, diseases of the central nervous system, alimentary tract diseases, and pain relief. Part of our program is devoted to animal health.
WE MANAGE THE ENTIRE LIFECYCLE OF OUR PRODUCTS
Our vertically integrated business model allows us to carefully manage and control every one of our products throughout their entire lifecycle. It allows us to provide high-quality, safe and effective generic medicines with added value to patients all over the world.
Operating figures are dynamic. The latest operating figures are published in the latest Annual Report.